Clinical Trials Phase I & IIA Summit

Sponsors often take for granted the fact that early phase trial design and operations can make or break future studies. When hard data is severely limited and is used to predict well beyond its boundaries, the quality of that data is absolutely paramount. The data obtained from phase 1 first-in-human studies through phase 2 proof-of-concept and dose range finding studies are vital to effectively designing future registration studies. Early phase clinical trials should be safe experiments on humans, not small-scale phase 3 trials. Therefore, it is beneficial to intelligently optimize early phase clinical activity to ensure successful trial execution and regulatory approval.
TOP FIVE REASONS TO ATTEND
*Implement adaptive study designs and predictive models to successfully accelerate early phase trials
*Improve vendor identification and communication from negotiation to study execution
*Overcome the evolving challenges of patient recruitment and retention for different diseases
*Leverage techniques to help identify genetic predisposition and risk factors for adverse events and drug reactions
*Discuss innovative strategies to optimize early phase clinical trial operations

Others Details

Speakers: Michel Azoulay, Global Oncology Leader, SANOFI CLINICAL OPERATIONS STRATEGY, Wesley Day, Lead Global Clinical Development, MTDA, Martin Gutierrez, M.D., Director of the Drug Discovery and many more. Time: 8:00 am to 5:00 pm